

PRESS RELEASE

Corbion nv
Piet Heinkade 127 1019 GM Amsterdam
PO Box 349 1000 AH Amsterdam
The Netherlands

T +31 (0)20 590 6911
Press@corbion.com
www.corbion.com

DATE 12 August 2015

Corbion Q2 and first half 2015 results

Corbion reported Q2 2015 sales of € 232.3 million, an increase of 23.4% compared to Q2 2014. Organic sales growth was 4.5%, mostly driven by volume growth. EBITDA excluding one-off items in Q2 2015 increased by 49.6% to € 40.1 million. Organic EBITDA growth in Q2 2015 amounted to 23.1%.

"We can look back on a strong second quarter. Biobased Ingredients delivered organic sales growth close to the upper bound of the 2015-2018 guidance CAGR range. EBITDA grew strongly, driven by organic growth, the continuing strength of the US dollar, and the benefits of our productivity improvement program Streamline, which are coming through at a more rapid pace than initially expected. We are making good progress with the execution of our strategy "Disciplined Value Creation", comments Tjerk de Ruiter, CEO.

Key financial highlights Q2 2015 and HY 2015:

- Net sales in Q2 increased by 23.4% to € 232.3 million, 4.5% organic growth
- EBITDA before one-off items in Q2 was € 40.1 million, an increase of 49.6% (an organic increase of 23.1%). EBITDA margin before one-off items was 17.3% in Q2 (Q2 2014: 14.2%)
- Capex in HY 2015 was € 27.3 million. Net debt at half year-end 2015 was € 72.1 million (Q4 2014: net cash of € 5.8 million)
- One-off items included in EBIT in HY 2015 of € 1.3 million, related to the Grandview incident
- The productivity improvement program Streamline is on track. The positive impact on the Q2 2015 EBITDA was € 4.3 million
- EPS HY 2015 was € 0.55 (HY 2014: € 0.00)
- We distributed an extraordinary dividend of € 50 million on 12 June 2015. The share buyback program that commenced in March reached € 31.9 million by June 30, around two thirds of the € 50 million targeted total by the end of 2015

€ million	Q2 2015	Q2 2014	YTD 2015	YTD 2014
Net sales	232.3	188.3	452.3	371.0
EBITDA excluding one-off items	40.1	26.8	77.3	51.9
EBITDA	39.9	24.0	77.1	49.1
EBITDA margin excluding one-off items	17.3%	14.2%	17.1%	14.0%
ROCE	20.7%	12.3%	20.2%	12.2%

PRESS RELEASE

Management review Q2 2015

Net sales

Net sales in Q2 increased by 23.4% to € 232.3 million (Q2 2014: € 188.3 million) due to organic growth (4.5%), acquisition effect (1.5%), and currency movements (17.4%). The currency impact was mainly driven by a stronger US dollar against the euro. Organic sales growth in Biobased Ingredients was 3.5%, comprising volume growth 3.7%, and price/mix effects -0.2%. Volume growth in Food was driven by Bakery and Meat. Sales growth in Biochemicals was notably in Electronics and Pharma. Organic growth in Biobased Innovations was driven by Bioplastics.

Q2 2015 compared to Q2 2014:

	Total growth	Currency	Total growth at constant currency	Acquisitions	Organic	Price/Mix	Volume
Biobased Ingredients	22.3%	17.3%	5.0%	1.5%	3.5%	-0.2%	3.7%
- Food	23.7%	18.6%	5.1%	1.7%	3.4%	-0.5%	3.9%
- Biochemicals	17.8%	13.0%	4.8%	0.8%	4.0%	1.4%	2.6%
Biobased Innovations	183.3%	34.0%	149.3%	0.0%	149.3%	98.6%	50.7%
Total	23.4%	17.4%	6.0%	1.5%	4.5%	0.4%	4.1%

EBITDA

EBITDA (excluding one-off items) increased by 49.6% to € 40.1 million. This increase was driven by organic growth of 23.1% and a positive currency impact of € 6.2 million. Organic growth was mainly driven by increased volumes as well as benefits from our productivity improvement program Streamline (€ 4.3 million).

Management review HY 2015

Net sales

Net sales in HY 2015 increased by 21.9% to € 452.3 million (2014: € 371.0 million) driven by currencies (16.5%), acquisition (0.7%), and organic growth (4.7%). Exchange rate movements impacted the sales figures positively by € 61.2 million mainly driven by a stronger US dollar. The acquisition impact is related to our acquisition of the Archer Daniels Midland (ADM) lactic acid business effective as of 31 March 2015.

Organic growth in the Biobased Ingredients business unit of 3.9% was driven by both business segments. In business segment Food, volume growth (4.0%) was driving organic growth (3.4%). Price/mix in Food was slightly negative (-0.6%). In the Biochemicals business segment, price/mix increased by 4.5% driven by strong Medical Biomaterial sale and the lower contribution of Feed acidifiers. The growth in Biobased Innovations was driven by Bioplastics.

PRESS RELEASE

HY 2015 compared to HY 2014:

	Total growth	Currency	Total growth at constant currency	Acquisitions	Organic	Price/Mix	Volume
Biobased Ingredients	21.1%	16.5%	4.6%	0.7%	3.9%	0.6%	3.3%
- Food	22.4%	18.1%	4.3%	0.9%	3.4%	-0.6%	4.0%
- Biochemicals	17.4%	11.6%	5.8%	0.4%	5.4%	4.5%	0.9%
Biobased Innovations	102.9%	17.4%	85.5%	0.0%	85.5%	46.8%	38.7%
Total	21.9%	16.5%	5.4%	0.7%	4.7%	1.1%	3.6%

EBITDA

EBITDA (excluding one-off items) increased by 48.9% to € 77.3 million which included a positive currency impact of € 10.2 million. Biobased Ingredients' EBITDA increased by 38.3% which was mainly driven by currencies and organic growth which comprises a positive volume growth and reduced costs. Streamline contributed € 6.8 million to the EBITDA growth. The Biobased Innovations EBITDA increase was mainly driven by sales.

Depreciation and amortization

Depreciation and amortization were € 22.9 million (2014: € 21.4 million).

Operating result

Operating result excluding one-off items increased by € 24.1 million, or 79.0%, to € 54.6 million in 2015 (2014: € 30.5 million).

One-off items

In HY we incurred one-off items of € 1.3 million in operating result, related to the Grandview incident in March 2015. We expect that the repair and remediation costs directly related to the incident will be covered by insurance.

Financial income and charges

Net financial charges remained relatively stable at € 2.9 million, an increase of € 0.3 million compared to HY 2014.

PRESS RELEASE

Taxes

The tax expenses on our operations in HY 2015 amounted to € 15.6 million compared to an expense of € 6.1 million in HY 2014. The major reason for the increase is the improved operating result (HY 2014 included a € 17.5 million impairment), from € 7.3 million (HY 2014) to € 50.2 million.

Balance sheet

Capital employed including goodwill increased, compared to year-end 2014, by € 33.1 million to € 536.0 million. The movements were:

€ million	
Capital expenditure on (in)tangible fixed assets	27.3
Depreciation / amortization / impairment of (in)tangible fixed assets	-23.9
Disposal of fixed assets	-4.8
Working capital increase	15.7
Exchange rate differences	17.8
Other	1.0

Capital expenditures in HY 2015 amounted to € 27.3 million which includes the unexpected replacement investment as a result of the Grandview incident and the acquired lactic acid business from ADM .

We divested the former head office in Diemen, The Netherlands for a total amount of € 5.4 million which contributed € 0.1 million positively to the operating result.

Trade working capital increased by € 21.5 million to € 129.6 million. This increase is the balance of an increase of € 15.7 million before currency effects and a currency effect of € 5.8 million.

Shareholders' equity decreased by € 44.8 million to € 463.9 million. The movements were:

- The positive result after taxes of € 34.6 million
- A decrease of € 9.1 million related to the dividend for financial year 2014
- A decrease of € 49.2 million related to the extraordinary cash dividend
- A decrease of € 33.1 million related to the share buyback program
- Positive exchange rate differences of € 13.5 million due to the translation of equity denominated in currencies other than the euro
- Negative movement of € 5.0 million in the hedge reserve
- Net share based remuneration costs charged to result of € 0.4 million
- Effects of defined benefit plan and tax effects € 3.1 million.

Between March and end-June 2015 we repurchased shares in the amount of € 33.1 million of the € 50 million targeted total. We expect to complete the share buyback program and the accompanying cancellation of these shares before the end of 2015.

PRESS RELEASE

At half year-end 2015 the ratio between balance sheet total and equity was 1:0.6 (year-end 2014: 1:0.6).

Cash flow/financing

Cash flow from operating activities increased compared to year-end 2014 by € 8.3 million to € 35.3 million. This is the balance of the higher operational cash flow before movements in working capital of € 27.4 million, a negative impact of the movement in working capital and provisions of € 12.7 million, and higher taxes and interest paid of € 6.4 million.

The cash flow required for investment activities decreased compared to 2014 by € 22.0 million to € 22.7 million. Capital expenditures accounted for most (€ 27.8 million) of this cash outflow, partly compensated by cash inflow of € 5.4 million as a result of divested assets.

The net debt position at the half year-end 2015 was € 72.1 million, an increase of € 77.9 million compared to year-end 2014, mainly due to dividend payment, the share buyback program, capital expenditures, and the increase in working capital compared to the year-end, partly compensated by the positive cash flow from operating activities before working capital and provisions.

At half year-end 2015, the ratio of net debt to EBITDA was 0.5x (year-end 2014: -0.1x due to a net cash position). The interest cover for HY 2015 was 27.7x (2014: 23.2x). We continue to stay well within the limits of our financing covenants.

Outlook 2015

For 2015, in our business segment Food, we anticipate growth at the upper half of our guidance range. In our business segment Biochemicals, due to the more difficult comparison we expect to grow near the lower end of the guidance range in 2015. The majority of the targeted € 20 million savings from our Streamline program will be achieved in 2015 rather than in 2016. In Biobased Innovations, we anticipate in H2 a higher R&D expense level. Overall we expect for H2 a slightly lower EBITDA excluding one-off items, compared to H1 2015.

PRESS RELEASE

Segment information

Biobased Ingredients

€ million	Q2 2015	Q2 2014		YTD 2015	YTD 2014
Net sales	228.9	187.1		445.2	367.5
Organic growth	3.5%	1.0%		3.9%	1.7%
EBITDA	40.6	27.3		79.9	55.1
EBITDA excl. one-off items	40.8	30.1		80.1	57.9
EBITDA margin excl. one-off items	17.8%	16.1%		18.0%	15.8%
ROCE	26.1%	19.9%		26.2%	19.8%
Average capital employed	481.9	425.5		474.3	417.9

In Q2, the Biobased Ingredients business unit showed sales growth of 22.3% driven by organic growth of 3.5% and a currency impact of 17.3%. The organic growth of 3.5% was towards the top end of the guidance range (2015-2018 CAGR) of 2-4%.

At the end of Q1, we acquired the lactic acid business of ADM. The transaction included the sales and delivery of lactic acid, sodium lactate, and potassium lactate products. No production facilities or personnel were acquired.

Business segment Food

€ million	Q2 2015	Q2 2014		YTD 2015	YTD 2014
Net sales	177.9	143.8		338.7	276.8
Organic growth	3.4%	-2.2%		3.4%	-1.8%
EBITDA	34.3	27.1		64.9	50.1
EBITDA excl. one-off items	34.5	27.1		65.1	50.1
EBITDA margin excl. one-off items	19.4%	18.8%		19.2%	18.1%

Q2 was another strong quarter for the Food segment with organic growth of 3.4%, slightly above the guidance range (2015-2018 CAGR) of 1-3%. This performance was mainly driven by the Bakery and Meat results.

PRESS RELEASE

In the US, our bakery activities benefited from the general consumer recovery in addition to good results with our innovative products in bread and sweet products. This was despite a temporary production disruption created by the Grandview incident.

Meat net sales grew across all regions. In the US, our Meat business grew for the third quarter in a row. Although we are experiencing lower than anticipated switching activity by our customers to low-cost-in-use alternatives, many of our customers continue to seek cost advantages for their preservative solutions, and we stay focused on protecting our positions in this market. There was good growth in premium label-friendly products in the US. Growth in Meat in the rest of the world was driven by progress in Latin America and Asia.

In Beverages, Confectionery, and Dairy, we struggled to grow mainly as a result of difficult market conditions and the adverse impact of the Grandview incident.

Business segment Biochemicals

€ million	Q2 2015	Q2 2014		YTD 2015	YTD 2014
Net sales	51.0	43.3		106.5	90.7
Organic growth	4.0%	13.0%		5.4%	13.6%
EBITDA	10.8	9.8		23.4	19.3
EBITDA excl. one-off items	10.8	9.8		23.4	19.3
EBITDA margin excl. one-off items	21.2%	22.6%		22.0%	21.3%

In Q2 2015, business segment Biochemicals delivered organic growth of 4.0%, slightly below the guidance range (2015-2018 CAGR) of 5-8%. Sales growth was more subdued due to a slowdown in lower cost/lower price feed acidifiers and the adverse impact of the Grandview incident. The strongest growth markets were Electronics and Pharma. The Q2 growth rate in Medical Biomaterials and Agrochemicals moderated after strong growth in previous successive quarters.

Central costs

€ million	Q2 2015	Q2 2014		YTD 2015	YTD 2014
EBITDA	(4.5)	(9.6)		(8.4)	(14.3)
EBITDA excl. one-off items	(4.5)	(6.8)		(8.4)	(11.5)

Central costs improved versus last in year in both Q2 and HY, due to the start of benefits of program Streamline.

PRESS RELEASE

Biobased Innovations

€ million	Q2 2015	Q2 2014		YTD 2015	YTD 2014
Net sales	3.4	1.3		7.1	3.5
Organic growth	149.3%	27.4%		85.5%	71.5%
EBITDA	(0.8)	(3.3)		(2.8)	(6.0)
EBITDA excl. one-off items	(0.8)	(3.2)		(2.8)	(6.0)
EBITDA margin excl. one-off items	-23.8%	-257.2%		-39.8%	-170.6%
Average capital employed	63.7	73.6		63.1	75.3

Net sales in business unit Biobased Innovations grew by 149.3% in Q2 2015, albeit from a low level. The lower EBITDA loss in Q2 2015 compared to last year was mostly due to the strong organic sales growth in Bioplastics and an increased contribution from the succinic acid activities. Due to workload phasing, R&D spend in the quarter was relatively modest.

At the strategy update in October 2014 we announced a new strategy for the PLA market such that we will move downstream into PLA production. In May we reached the main milestone for the construction of a new 75 kT plant, having secured upfront customer commitment for at least one-third of plant capacity. Pre-engineering for this plant is in full progress and is expected to run until the end of the year. In order to further accelerate market acceptance of PLA, we have already begun to test, validate, and sell pre-marketing volumes of PLA.

Risks

Our approach to risk management aims to achieve a reasonable level of assurance, in line with the Enterprise Risk Management framework of the Committee of Sponsoring Organizations of the Treadway Commission (COSO – ERM). Our approach aims to embed risk awareness and risk management at all levels of Corbion to ensure risk decisions are taken and evaluated consciously and properly.

The principal risks faced by the company during the first half of the financial year were the same as those identified at year-end 2014 and management does not presently anticipate any material changes to the nature of the risks affecting Corbion's business over the second half of the financial year. A description of Corbion's risk management practices, principal risks and how they impact Corbion's business is provided in our 2014 Annual Report.

PRESS RELEASE

Responsibility statement

The Board of Management hereby declares that, to the best of their knowledge, the interim financial statements for the first half-year of 2015 have been prepared in accordance with IAS 34, "Interim Financial Reporting" and give a true and fair view of the assets, liabilities, financial position and profit of Corbion nv and its consolidated companies included in the consolidation as a whole. Furthermore, to the best of our knowledge, this half-year report includes a fair view of the information required pursuant to Section 5:25d subsections 8 and 9 of the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht).

For more information, please contact:

Press: Saskia Nuijten, Director Corporate Communications
T +31 (0)20 590 6320, M +31 (0)6 21 812 453

Analysts and investors:

Jeroen van Harten, Director Investor Relations
T +31 (0)20 5906293, M +31(0)6 21 577 086

Background information:

Corbion: biobased solutions, designed by science, powered by nature, and delivered through dedication.

Corbion is the global market leader in lactic acid, lactic acid derivatives and lactides, and a leading company in functional blends containing enzymes, emulsifiers, minerals and vitamins. The company delivers high performance biobased products made from renewable resources and applied in global markets such as bakery, meat, pharmaceuticals and medical devices, home and personal care, packaging, automotive, coatings and adhesives. Its products have a differentiating functionality in all kinds of consumer products worldwide. In 2014, Corbion generated annual sales of € 770.1 million and had a workforce of 1,893 employees. Corbion is listed on NYSE Euronext Amsterdam. For more information: www.corbion.com

Media call

A media call will be held at 8:00 (CET) hours on Wednesday 12 August 2015 with Msrs. Tjerk de Ruiter and Eddy van Rhede van der Kloot.

Call details: Dial in: +31 (0)20 716 8257 / Conference ID: 2198908

Analyst presentation (Webcast)

An analyst meeting will be held at the Crowne Plaza Amsterdam - South (George Gershwinlaan 101, 1082 MT Amsterdam, the Netherlands) from 11.00 hours (CET) on Wednesday 12 August 2015.

The presentation can be followed live via

http://player.companywebcast.com/corbion/20150812_1/en/Player from 11.00 hours (CET).

The slides used during the presentation can be downloaded from the Investor Relations section on our website.

PRESS RELEASE

1. Consolidated income statement

<i>millions of euros</i>	1st Half-year	
	2015	2014 (restated)
Net sales	452.3	371.0
Costs of raw materials and consumables	-233.0	-184.3
Production costs	-67.2	-60.7
Impairment of tangible fixed assets	-1.0	-17.5
Warehousing and distribution costs	-24.8	-21.3
Gross profit	126.3	87.2
Selling expenses	-30.1	-30.5
Research and development costs	-14.1	-14.7
General and administrative expenses	-28.8	-31.8
Operating result	53.3	10.2
Financial income		0.1
Financial charges	-2.9	-2.7
Results from joint ventures and associates	-0.2	-0.3
Result before taxes	50.2	7.3
Taxes	-15.6	-6.1
Result after taxes	34.6	1.2
Per common share in euros		
Basic earnings	0.55	0.00
Diluted earnings	0.54	0.00

PRESS RELEASE

2. Consolidated statement of comprehensive income

<i>millions of euros</i>	1st Half-year	
	2015	2014 (restated)
Result after taxes	34.6	1.2
Other comprehensive results to be recycled:		
Translation reserve	13.5	4.4
Hedge reserve	-5.0	1.2
Taxes relating to other comprehensive results to be recycled	3.3	-0.7
Total other comprehensive results to be recycled	11.8	4.9
Other comprehensive results not to be recycled:		
Defined benefit arrangements	-0.2	-0.7
Total other comprehensive results not to be recycled	-0.2	-0.7
Total comprehensive result after taxes	46.2	5.4

PRESS RELEASE

3. Consolidated statement of financial position

<i>before profit appropriation, millions of euros</i>	As at 30-06-2015	As at 31-12-2014
Assets		
Property, plant, and equipment	297.0	288.7
Intangible fixed assets	134.1	122.9
Loans, receivables, and other	3.1	3.3
Joint ventures and associates	6.7	6.6
Deferred tax assets	10.5	11.6
Total non-current assets	451.4	433.1
Inventories	140.9	128.4
Receivables	113.4	103.9
Tax assets	0.9	2.3
Cash and cash equivalents	42.4	111.4
Assets held for sale		4.5
Total current assets	297.6	350.5
Total assets	749.0	783.6
Equity and liabilities		
Equity	463.9	508.7
Provisions	11.5	11.8
Deferred tax liabilities	8.4	9.4
Non-current liabilities	38.5	35.6
Total non-current liabilities	58.4	56.8
Interest-bearing current liabilities	76.0	70.0
Trade payables	60.0	57.0
Other non-interest-bearing current liabilities	72.6	66.9
Provisions	11.0	18.3
Tax liabilities	7.1	5.9
Total current liabilities	226.7	218.1
Total equity and liabilities	749.0	783.6

PRESS RELEASE

4. Consolidated statement of changes in equity

<i>before profit appropriation, millions of euros</i>	Share capital	Share premium reserve	Other reserves	Retained earnings	Total
As at 1 January 2014	18.7	73.0	14.1	399.0	504.8
Result after taxes				1.2	1.2
Other comprehensive result after tax			4.9	-0.7	4.2
Transfers to/from Other reserves			17.7	-17.7	
Total comprehensive result after tax			22.6	-17.2	5.4
Cash dividend				-5.6	-5.6
Stock dividend	0.1	-0.1			
Share-based remuneration transfers			-0.8	0.8	
Share-based remuneration charged to result			1.3		1.3
Withdrawal of shares	-2.7	-10.0		12.7	
Total transactions with shareholders	-2.6	-10.1	0.5	7.9	-4.3
As at 30 June 2014	16.1	62.9	37.2	389.7	505.9
As at 1 January 2015	16.1	62.9	58.9	370.8	508.7
Result after taxes				34.6	34.6
Other comprehensive result after tax			11.8	-0.2	11.6
Transfers to/from Other reserves			1.4	-1.4	
Total comprehensive result after tax			13.2	33.0	46.2
Cash dividend				-58.3	-58.3
Stock dividend	0.1	-0.1			
Acquired company shares				-33.1	-33.1
Share-based remuneration transfers			-0.7	0.7	
Share-based remuneration charged to result			0.4		0.4
Total transactions with shareholders	0.1	-0.1	-0.3	-90.7	-91.0
As at 30 June 2015	16.2	62.8	71.8	313.1	463.9

PRESS RELEASE

5. Consolidated statement of cash flows

<i>millions of euros</i>	1st Half-year	
	2015	2014 (restated)
Cash flow from operating activities		
Result after taxes	34.6	1.2
Adjusted for:		
• Depreciation/amortization of fixed assets	22.9	21.4
• Impairment of fixed assets	1.0	17.5
• Result from divestments of fixed assets	0.1	0.1
• Share-based remuneration	0.4	1.3
• Interest income		-0.1
• Interest expense	2.7	2.5
• Other financial income and charges	0.2	-0.1
• Results from joint ventures and associates	0.2	0.4
• Taxes	15.6	6.1
Cash flow from operating activities before movements in working capital and provisions	77.7	50.3
Movement in provisions	-9.1	1.2
Movements in working capital:		
• Receivables	-9.6	-3.8
• Inventories	-7.1	-7.3
• Non-interest-bearing current liabilities	-2.1	-5.3
Cash flow from business operations	49.8	35.1
Interest received		0.1
Interest paid	-2.4	-3.6
Tax paid on profit	-12.1	-4.6
Cash flow from operating activities	35.3	27.0
Cash flow from investment activities		
Investment joint ventures and associates	-0.3	-0.7
Investment other financial assets		-4.2
Capital expenditure on (in)tangible fixed assets	-27.8	-39.9
Divestment of (in)tangible fixed assets	5.4	0.1
Cash flow from investment activities	-22.7	-44.7
Cash flow from financing activities		
Repayment of interest-bearing debts	-0.1	-0.8
Acquisition of company shares	-31.9	
Paid-out dividend	-51.2	-5.1
Cash flow from financing activities	-83.2	-5.9
Net cash flow	-70.6	-23.6
Effects of exchange rate differences on cash and cash equivalents	1.6	0.3
Increase/decrease cash and cash equivalents	-69.0	-23.3
Cash and cash equivalents at start of financial year	111.4	123.9
Cash and cash equivalents at close of financial year	42.4	100.6

PRESS RELEASE

6. Accounting information

Principles for the valuation of assets and liabilities and determination of the result

This condensed interim financial information for the half-year ended 30 June 2015 complies with IFRS and has been prepared in accordance with IAS 34, 'Interim financial reporting'. The interim condensed financial report should be read in conjunction with the annual financial statements for the year ended 31 December 2014. In preparing these condensed interim financial statements the main estimates and judgements made by the Board of Management when applying Corbion's accounting policies, were similar to those applied to the annual financial statements for the year ended 31 December 2014.

The figures in this half-year report have not been audited or reviewed by an external auditor.

Overview of prior period adjustments

Contractual obligations towards the former Board of Management

As discussed in the annual financial statements for the year ended 31 December 2014, Corbion discovered during 2014 that the full effects of contractual obligations towards the former Board of Management were not completely included in the financial statements of 2013. To correct this the financial statements for 2013 were restated. Of the total € 2.0 million result after taxes prior period adjustment, € 1.1 million had already been accounted for in the H1 2014 figures and has therefore now been released in the comparative figures 2014. As a result, the general and administrative expenses decreased by € 1.1 million and taxes increased by € 0.3 million.

Change in presentation

Certain prior year comparatives have been reclassified to conform to the current year's presentation. In the H1 2014 income statement, these reclassifications increased production costs by € 0.9 million (HY 2014: € 59.8 million), selling expenses by € 0.5 million (HY 2014: € 30.0 million) and financing expenses by € 0.3 million (HY 2014: € 2.4 million) and decreased research and development by € 0.4 million (HY 2014: € 15.1 million) and general and administrative expenses by € 1.3 million (HY 2014: € 34.2 million).

Accounting policies:

The accounting policies adopted are consistent with those of the previous financial year.

Related party transactions

There were no material related party transactions in the first half of 2015.

Events after balance sheet date

On 10 August 2015, Corbion and MedinCell announced they are establishing a 50/50 joint venture for the supply of PEG (polyethyleneglycol) and PLA (polylactic acid) based co-polymers in the field of controlled release drug delivery.

Contingent assets

The insurance proceeds to be received after balance sheet date as a result of the Grandview explosion are expected to be between USD 5 million and USD 10 million.

PRESS RELEASE

7. Segment information

As a result of the strategy update in October 2014, Corbion has made an updated assessment of the reportable segments. In line with the revised management responsibilities and internal management reporting for its strategic decision-making process Corbion now distinguishes between Biobased Ingredients and Biobased Innovations. For IFRS segmentation purposes Biobased Ingredients has been segmented into two further businesses, Food and Biochemicals. The unallocated part of total operations mainly comprises central activities. As a result of the strategy update, prior year segmentation has been restated.

In the Food segment, our food ingredients portfolio keeps food safe and fresh, from creation to consumption, and as such, reduces food waste. It ranges from preservation ingredients to microbial spoilage prevention and ingredients that keep food fresh and tasty throughout shelf life.

The combined use of industry knowledge and scientific creativity enables us to offer industry-leading biobased technology and sustainability gains. Our future-focused thinking impacts every industry ranging from baking, meat, and dairy to confectionery and beverage.

In the Biochemicals segment, our biobased chemicals derived from renewable resources such as sugar or starch, are a sustainable alternative to fossil-based chemicals in various applications, including cleaning detergents, hand soap, coatings, and animal feed.

Offering improved performance and multiple benefits, our biobased solutions are versatile and, at the same time, provide lower cost in use with enhanced environmental credentials.

Our Biobased Innovations business unit creates new business platforms to help advance biotechnology developments. Our PLA/lactide business and the succinic-acid joint venture with BASF (Succinity) are part of this unit. Our longer-term development projects, such as our gypsum-free fermentation technology, lactic acid based on second-generation biomass, and FDCA are also included in this business unit. We will drive for growth via a disciplined stage-gate investment approach using our own core technology platforms, acquired or licensed technologies, and partnerships to improve our chance of success.

Segment information by business area

1st Half-year millions of euros	Food		Biochemicals		Biobased Innovations		Unallocated (central activities)		Corbion	
	2015	2014	2015	2014	2015	2014	2015	2014	2015	2014
Income statement information										
Net sales	338.7	276.8	106.5	90.7	7.1	3.5			452.3	371.0
Operating result	51.6	39.5	17.7	14.0	-7.7	-28.6	-8.3	-14.7	53.3	10.2
One-off items included in operating result	1.3					17.5		2.8	1.3	20.3
Alternative non-IFRS performance measures										
EBITDA	64.9	50.1	23.4	19.3	-2.8	-6.0	-8.4	-14.3	77.1	49.1
One-off items included in EBITDA	0.2							2.8	0.2	2.8
EBITDA excluding one-off items	65.1	50.1	23.4	19.3	-2.8	-6.0	-8.4	-11.5	77.3	51.9
Ratios alternative non-IFRS performance measures										
EBITDA margin % excluding one-off items	19.2	18.1	22.0	21.3	-39.4	-171.4			17.1	14.0

Corbion generates almost all of its revenues from the sale of goods.

One-off items HY 2015

The one-off items 2015 are related to the Grandview explosion, consisting of the following components:

- An impairment of tangible fixed assets of € 1.1 million;
- Insurance proceeds of € 3.1 million;
- Incurred tolling and other additional costs of € 3.3 million.

Information on the use of alternative non-IFRS performance measures

In the above table and elsewhere in the financial statements a number of non-IFRS performance measures is presented. Management is of the opinion that these so-called alternative performance measures might be useful for the readers of these financial statements. Corbion management uses these performance measures to make financial, operational, and strategic decisions and evaluate performance of the segments. The alternative performance measures can be calculated as follows:

- EBITDA is the operating result before depreciation, amortization, and impairment of (in)tangible fixed assets
- EBITDA margin is EBITDA divided by net sales x 100

PRESS RELEASE

8. Financial instruments

Valuation of financial instruments

Corbion measures fair values using the following fair value hierarchy that reflects the significance of the inputs used in making the measurements:

- Level 1: Fair value measurements based on quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Fair value measurements based on inputs other than level 1 quoted prices that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: Fair value measurements based on valuation techniques that include inputs for the asset or liability that are based on observable market data (unobservable inputs).

Breakdown valuation of financial instruments

30 June 2015	Level 1	Level 2	Level 3	Total
Derivatives				
• Foreign exchange contracts		0.4		0.4
• Commodity swaps/collars		-1.6		-1.6
Total asset		-1.2		-1.2

Breakdown fair values financial instruments

	30 June 2015		31 December 2014	
	Carrying amount	Fair value	Carrying amount	Fair value
Financial fixed assets				
• Loans, receivables, and other	1.2	1.2	1.4	1.4
• Loans non-interest-bearing	1.9	1.9	1.9	1.9
Receivables				
• Trade receivables	101.4	101.4	94.9	94.9
• Other receivables	8.6	8.6	5.7	5.7
• Accruals and deferred income	3.0	3.0	2.6	2.6
Cash				
• Dutch treasury certificates, money market funds, and short-term deposits			60.0	60.0
• Cash other	42.4	42.4	51.4	51.4
Interest-bearing liabilities				
• Private placement 2010 (net investment hedge)	-113.5	-116.4	-104.6	-107.3
• Financial lease commitments	-0.1	-0.1	-0.1	-0.1
• Other debts	-0.9	-0.9	-0.9	-0.9
Non-interest-bearing liabilities				
• Trade payables	-60.0	-60.0	-57.0	-57.0
• Other payables	-71.0	-71.0	-66.9	-66.9
Derivatives				
• Foreign exchange contracts	0.4	0.4	0.7	0.7
• Commodity swaps/collars	-1.6	-1.6	-3.3	-3.3
Total	-88.2	-91.1	-14.2	-16.9

Fair values are determined as follows

- The fair value of financial fixed assets does not significantly deviate from the book value.
- The fair value of receivables equals the book value because of their short-term character.
- Cash and cash equivalents are measured at nominal value which, given the short-term and risk-free character, corresponds to the fair value.
- Market quotations are used to determine the fair value of debt owed to private parties, credit institutions and other debts. As there are no market quotations for most of the loans the fair value of short- and long-term loans is determined by discounting the future cash flows at the yield curve applicable as at the reporting date.
- Financial lease commitments: the fair value is estimated at the present value of the future cash flows, discounted at the interest rate for similar contracts which is applicable as at the reporting date. This fair value equals the book value.
- Given the short-term character, the fair value of non-interest-bearing liabilities equals the book value.
- Currency and interest derivatives are measured on the basis of the present value of future cash flows over the remaining term of the contracts, using the bank interest rate (such as Euribor) as at the reporting date for the remaining term of the contracts. The present value in foreign currencies is converted using the exchange rate applicable as at the reporting date.
- Commodity derivatives are measured on the basis of the present value of future cash flows, using market quotations or own variable market price estimations of the involved commodity as at the reporting date.

PRESS RELEASE

9. Key figures

<i>millions of euros</i>	1st Half-year	
	2015	2014
Net sales	452.3	371.0
Operating result	53.3	10.2
EBITDA excluding one-off costs	77.3	51.9
Result after taxes	34.6	1.2
Earnings in euros ¹ *	0.55	0.00
Diluted earnings in euros ¹ *	0.54	0.00
Key data per common share		
Number of issued common shares	62,391,505	62,041,761
Number of common shares with dividend rights	60,091,418	61,544,895
Weighted average number of outstanding common shares*	61,187,987	61,618,654
Price as at 30 June	17.74	15.40
Highest price in half-year	20.26	17.27
Lowest price in half-year	12.70	15.29
Market capitalization as at 30 June	1,066	948
Other key data		
Cashflow from operating activities	35.3	27.0
Cash flow from operating activities per common share, in euros ¹	0.58	0.42
Depreciation/amortization fixed assets	22.9	21.4
Capital expenditure on (in) tangible fixed assets	27.3	35.1
Number of issued cumulative preference shares	2,574,281	2,574,281
Equity per share in euros ²	7.40	7.89
Ratios		
ROCE % ³	20.2	12.2
EBITDA margin % ⁴	17.1	14.0
Result after taxes / net sales %	7.6	0.3
Number of employees at closing date	1,752	1,876
Net debt position/EBITDA ⁵	0.5	-0.1
Interest cover ⁶	27.7	23.2
Balance sheet figures as per 30/06/2015 and 31/12/2014		
Non-current assets	451.4	433.1
Current assets excluding cash and cash equivalents	255.2	239.1
Non-interest-bearing current liabilities	139.7	129.8
Net debt position ⁷	72.1	-5.8
Provisions	30.9	39.5
Equity	463.9	508.7
Capital employed ⁸	536.0	502.9
Average capital employed ⁸	537.4	505.2
Balance sheet total : equity	1:0.6	1:0.6
Net debt position : equity	1:6.4	1:-87.7
Current assets : current liabilities	1:0.8	1:0.6

*previous year is restated for stock dividend

1 Per common share in euros after deduction of dividend on cumulative preference shares.

2 Equity per share is equity as per 30/06 divided by the number of shares with dividend rights.

3 Return on capital employed (ROCE) is defined by Corbion as 2x (continued EBIT excluding one-off costs for half-year, including results from joint ventures and associates) divided by the average capital employed x 100.

4 EBITDA margin % is EBITDA excluding one-off costs divided by net sales x 100.

5 EBITDA is "Earnings Before Interest, Taxes, Depreciation and Amortization and impairment of (in)tangible fixed assets" here for the preceeding 12-month period including acquisition and divestment results, including discontinued operations and excluding one-off costs.

6 Interest cover is EBITDA as defined in Note 5 divided by net interest income and charges.

7 Net debt position comprises interest-bearing debts less cash and cash equivalents.

8 Capital employed and average capital employed is based on balance sheet book values.